-
Je něco špatně v tomto záznamu ?
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey
S. Greggi, F. Falcone, C. Scaffa, A. du Bois, EPP. Samartzis, E. Pujade-Lauraine, D. Cibula, R. Mądry, J. Korach, K. Gungorduk, IA. McNeish, V. Zanagnolo, C. Marth, AM. van Altena, G. Aravantinos, J. Sehouli, I. Vergote, A. Gonzalez Martin
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
NLK
ProQuest Central
od 2018-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2018-01-01 do Před 6 měsíci
PubMed
32354792
DOI
10.1136/ijgc-2019-001172
Knihovny.cz E-zdroje
- MeSH
- chirurgická onkologie statistika a číselné údaje MeSH
- cytoredukční chirurgie * MeSH
- gynekologie statistika a číselné údaje MeSH
- laparoskopie statistika a číselné údaje MeSH
- lidé MeSH
- nádory vaječníků diagnóza chirurgie MeSH
- nádory vejcovodů diagnóza chirurgie MeSH
- peritoneální nádory diagnóza chirurgie MeSH
- průzkumy a dotazníky MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVE: Laparoscopy is one of the diagnostic tools available for the complex clinical decision-making process in advanced ovarian, fallopian tube, and peritoneal carcinoma. This article presents the results of a survey conducted within the European Network of Gynaecological Oncology Trial (ENGOT) group aimed at reviewing the current patterns of practice at gynecologic oncology centers with regard to the evaluation of resection in advanced ovarian, fallopian tube, and peritoneal carcinoma. METHODS: A 24-item questionnaire was sent to the chair of the 20 cooperative groups that are currently part of the ENGOT group, and forwarded to the members within each group. RESULTS: A total of 142 questionnaires were returned. Only 39 respondents (27.5%) reported using some form of clinical (not operative) score for the evaluation of resection. The frequency of use of diagnostic laparoscopy to assess disease status and feasibility of resection was as follows: never, 21 centers (15%); only in select cases, 83 centers (58.5%); and routinely, 36 centers (25.4%). When laparoscopy was performed, 64% of users declared they made the decision to proceed with maximal effort cytoreductive surgery based on their personal/staff opinion, and 36% based on a laparoscopic score. To the question of whether laparoscopy should be considered the gold standard in the evaluation of resection, 71 respondents (50%) answered no, 66 respondents (46.5%) answered yes, whereas 5 respondents (3.5%) did not provide an answer. CONCLUSIONS: This study found that laparoscopy was routinely performed to assess feasibility of cytoreduction in only 25.4% of centers in Europe. However, it was commonly used to select patients and in a minority of centers it was never used . When laparoscopy was adopted, the treatment strategy was based on laparoscopic scores only in a minority of centers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020494
- 003
- CZ-PrNML
- 005
- 20240731110031.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ijgc-2019-001172 $2 doi
- 035 __
- $a (PubMed)32354792
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Greggi, Stefano $u Multicentre Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Group and Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy s.greggi@istitutotumori.na.it
- 245 10
- $a Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey / $c S. Greggi, F. Falcone, C. Scaffa, A. du Bois, EPP. Samartzis, E. Pujade-Lauraine, D. Cibula, R. Mądry, J. Korach, K. Gungorduk, IA. McNeish, V. Zanagnolo, C. Marth, AM. van Altena, G. Aravantinos, J. Sehouli, I. Vergote, A. Gonzalez Martin
- 520 9_
- $a OBJECTIVE: Laparoscopy is one of the diagnostic tools available for the complex clinical decision-making process in advanced ovarian, fallopian tube, and peritoneal carcinoma. This article presents the results of a survey conducted within the European Network of Gynaecological Oncology Trial (ENGOT) group aimed at reviewing the current patterns of practice at gynecologic oncology centers with regard to the evaluation of resection in advanced ovarian, fallopian tube, and peritoneal carcinoma. METHODS: A 24-item questionnaire was sent to the chair of the 20 cooperative groups that are currently part of the ENGOT group, and forwarded to the members within each group. RESULTS: A total of 142 questionnaires were returned. Only 39 respondents (27.5%) reported using some form of clinical (not operative) score for the evaluation of resection. The frequency of use of diagnostic laparoscopy to assess disease status and feasibility of resection was as follows: never, 21 centers (15%); only in select cases, 83 centers (58.5%); and routinely, 36 centers (25.4%). When laparoscopy was performed, 64% of users declared they made the decision to proceed with maximal effort cytoreductive surgery based on their personal/staff opinion, and 36% based on a laparoscopic score. To the question of whether laparoscopy should be considered the gold standard in the evaluation of resection, 71 respondents (50%) answered no, 66 respondents (46.5%) answered yes, whereas 5 respondents (3.5%) did not provide an answer. CONCLUSIONS: This study found that laparoscopy was routinely performed to assess feasibility of cytoreduction in only 25.4% of centers in Europe. However, it was commonly used to select patients and in a minority of centers it was never used . When laparoscopy was adopted, the treatment strategy was based on laparoscopic scores only in a minority of centers.
- 650 12
- $a cytoredukční chirurgie $7 D065426
- 650 _2
- $a nádory vejcovodů $x diagnóza $x chirurgie $7 D005185
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gynekologie $x statistika a číselné údaje $7 D006176
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a laparoskopie $x statistika a číselné údaje $7 D010535
- 650 _2
- $a nádory vaječníků $x diagnóza $x chirurgie $7 D010051
- 650 _2
- $a peritoneální nádory $x diagnóza $x chirurgie $7 D010534
- 650 _2
- $a chirurgická onkologie $x statistika a číselné údaje $7 D000071077
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Falcone, Francesca $u Multicentre Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Group and Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy
- 700 1_
- $a Scaffa, Cono $u Multicentre Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Group and Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy
- 700 1_
- $a Du Bois, Andreas, $d 1956- $u Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Group and Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte gGmbH, Essen, Germany $7 xx0320625
- 700 1_
- $a Samartzis, Eleftherios Pierre Pierre $u Swiss Group for Clinical Cancer Research (SAKK) and Department of Gynecology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Pujade-Lauraine, Eric $u Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire, gynécologiques et du sein (GINECO) and Department of Medical Oncology, Hôpital Hôtel-Dieu, Université Paris Descartes, Paris, France
- 700 1_
- $a Cibula, David $u Central and Eastern European Gynecologic Oncology Group (CEEGOG) and Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Mądry, Radoslaw $u Polish Gynecologic Oncology Group (PGOG) and Department of Gynecological Oncology, Poznan University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Korach, Jacob $u Israeli Society of Gynecologic Oncology (ISGO) and Department of Gynecologic Oncology, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Tel Aviv, Israel
- 700 1_
- $a Gungorduk, Kemal $u Turkish Society of Gynecologic Oncology (TRSGO) and Department of Gynecologic Oncology, Mugla Sitki Kocman University, Education and Research Hospital, Mugla, Turkey
- 700 1_
- $a McNeish, Iain A $u National Cancer Research Institute (NCRI) and Department of Surgery and Cancer, Imperial College London, London, United Kingdom
- 700 1_
- $a Zanagnolo, Vanna $u Mario Negri Gynecologic Oncology (MaNGO) Group and Department of Gynecologic Oncology, Istituto Europeo di Oncologia, Milan, Italy
- 700 1_
- $a Marth, Christian $u AGO-Austria and Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a van Altena, Anne M $u Dutch Gynaecological Oncology Group (DGOG) and Department of Obstetrics and Gynecology, Radboud University Medical Centre, Nijmegen, the Netherlands
- 700 1_
- $a Aravantinos, Gerasimos $u Ηellenic Cooperative Oncology Group (HeCOG) and Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
- 700 1_
- $a Sehouli, Jalid $u Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) and Department of Gynecologic Oncology, Charité Comprehensive Cancer Center Berlin, Berlin, Germany
- 700 1_
- $a Vergote, Ignace $u Belgium and Luxembourg Gynaecological Oncology Group (BGOG) and Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Gonzalez Martin, Antonio $u Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer $x 1525-1438 $g Roč. 30, č. 6 (2020), s. 819-824
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32354792 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20240731110030 $b ABA008
- 999 __
- $a ok $b bmc $g 1691128 $s 1140940
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 6 $d 819-824 $e 20200430 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $a Pubmed-20210728
